HTNB is linked to chromosome 12p, as shown in 6 unrelated families. 10, 11 The locus seems to be relevant to essential hypertension supported by a linkage study in Chinese hypertensive families without brachydactyly type E. 12 Furthermore, a recent genome-wide association study from Framingham also identified the location we report. 13 The molecular causes for HTNB are heterozygous missense, gain-of-function mutations in the gene encoding the cGMP-inhibited cAMP phosphodiesterase 3A (PDE3A). 14 PDE3A belongs to the PDE3 family, which catalyzes the hydrolysis of the intracellular second messengers, cAMP and cGMP. 15 PDE3A plays a prominent role in heart, vascular smooth muscle cells (VSMCs), oocytes, and platelets. 16 In HTNB, the mutational PDE3A enhances VSMC proliferation that together with increased constriction is likely causative for the increased peripheral vascular resistance. Hypertension arises in childhood, 17 and treatment modalities are flexible. 18 Nevertheless, conventional hypertension-induced target organ damage in the form of cardiac hypertrophy, hypertensive retinopathy, and kidney damage is remarkably mild. 19 PDE3A is abundant in platelets. 20 We investigated ventriculoarterial coupling and platelet function in HTNB patients. We used in vitro pharmacological testing to study the mutated enzymes and suggest that increasing cGMP in VSMC could be of therapeutic use in patients with HTNB.
Methods
After internal review-board (IRB, Charité University Medicine Berlin) approval, we invited 4 affected and 4 nonaffected members from our Turkish kindred with the T445N mutation to participate in clinical research center-based studies. Written informed consent was obtained from all participants. Detailed methods are available in the online-only Data Supplement.
Central Blood Pressure
Our technique is based on the wave reflection method using a common oscillometric cuff (ARCSolver) and was validated against the standard tonometric method, as well as compared with invasive aortic blood pressure measurements. 21, 22 During cardiovascular magnetic resonance imaging (CMR), a compatible blood pressure measurement device was used. Blood pressure was measured 3× at baseline and during handgrip testing.
Echocardiography
Transthoracic echocardiography (Vivid E9, GE Healthcare) was performed using a 4V-D active matrix 4D volume phased array transducer in steep left lateral decubitus position. A standardized ultrasound examination protocol was developed for this clinical study and applied in each patient. Electrocardiographic-guided loops using standard acoustic windows were stored for off-line image analysis. To assess left-ventricular (LV) size, volume, and contractility, a complete set of standardized views encompassing LV and atria was obtained at rest in 2-dimensional (2D) and color Doppler mode. A volume mode was used for 4D data sets. A pulsed Doppler at the tips of the mitral valve leaflets and pulsed tissue Doppler in the mitral valve plane were obtained to assess diastolic function and time intervals.
23,24

Cardiovascular Magnetic Resonance Imaging
All CMR scans were performed on a clinical 1.5 Tesla MR scanner (Avanto, Siemens Medical Solutions AG, Erlangen, Germany) using a 12-channel cardiac array coil. We performed cine imaging with a standard steady-state free precession sequence to assess cardiac structure and function. We acquired 3 long axes and a complete short-axis package covering the left ventricle from base to apex during repetitive breath holds in end-expiration. To assess aortic stiffness, we measured aortic distensibility and pulse wave velocity according to the transit time method by validated CMR techniques. 25, 26 
Handgrip Testing
For the handgrip test, the subject squeezed a rubber ball with 30% of his maximal voluntary force for 3 minutes. Handgrip testing was also performed during CMR imaging. A CMR compatible prototype was used (Sensory-Motor Systems Laboratory, Zurich, Switzerland) consisting of the plastic handgrip, a plastic fiber cable, an electronic switch box, and corresponding software measuring force by an optical principle.
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Platelet Aggregation
For the preparation of platelet-rich plasma, citrate anticoagulated blood samples were centrifuged at 100g for 10 minutes. Supernatant was carefully transferred to polypropylene tubes (Falcon tubes, BD Bioscience, Bedford). Platelet count was adjusted to 2×10 5 platelets/µL (accepted range, 1.9-2.1×10 5 platelets/µL) with blood group AB plasma and stored at 37°C until use. Platelets were activated with thrombin receptor activator peptide (TRAP) and collagen. Transmission of light through a platelet suspension was continuously measured over time with conventional automated data acquisition and analysis (Labview). Nine different concentrations of TRAP-6 (H-Ser-Phe-Leu-Leu-Arg-ASN-OH; Bachem Inc, Switzerland) and Collagen reagent Horm (Takeda Austria GmbH, Austria) were examined in replicates for each patient and control. Measurements of the area under the aggregation curve were plotted against the concentrations of each stimulus with DeltaGraph v7.0.1 software (Red Rock software, Inc and Equation Editor Design Sciences, Inc). Milrinone (1,6-dihydro-2-methyl-6-oxo-(3,4′-bipyridine)-5-carbonitrile) was used to inhibit platelet aggregation (SigmaAldrich). Platelets were preincubated with the inhibitor for 5 minutes. Milrinone concentrations between 0.03 and 100 µmol/L were tested for the inhibition of TRAP-6 and collagen-induced aggregation (100 and 33.3 µmol/L TRAP; 20 and 6.6 mg/mL collagen). 
Hypertension
Cell-Based Studies
We performed functional cAMP responsive element luciferase assays in HeLa cells transiently expressing the 6 HTNB PDE3A mutations in comparison with wild-type PDE3A. HeLa cells were transfected with an empty vector (sc300-w/o), a wild-type PDE3A (Origene, SC300151) expression construct, and the 6 full-length mutant PDE3A expression plasmids. HeLa cells were cotransfected with a cAMP responsive element regulating luciferase. The measured luciferase activity was dependent on the cellular cAMP level. A renilla luciferase vector was used for standardization.
Statistics
We used parametric statistics (repeated measures ANOVA where indicated) on normally distributed data. We relied on nonparametric statistics where indicated. For cell-based experiments, the functional in vitro experiments were reproduced 2 to 6 times. Numbers (n) of experiments are mentioned in the figure legends. Significance was determined by nonparametrical Wilcoxon rank-sum and Mann-Whitney tests (***P<0.001, **P<0.01, and *P<0.05). Scatter plots show mean, and T-bars indicate SEM.
Results
We were able to recruit 4 affected persons (AFF) harboring the PDE3A T445N mutation and 4 nonaffected relatives (NON) for this study (Table) . Heart rate was similar in affected (1 man and 3 women; age, 16-60 years) and nonaffected family members (2 men and 2 women; age, 23-58 years). Central systolic blood pressure and central diastolic blood pressure tended to be higher in affected family members ( Figure 1A ). One older male nonaffected family member (046) was obese, hypertensive (treated with valsartan and amlodipine), and had known atherosclerosis. Affected family members showed no profound changes in left ventricular mass, cardiac output, distensibility of the ascending aorta, or in aortic pulse wave velocity measured by CMR. The highest values for aortic pulse wave velocity associated with low aortic distensibility were obtained in AFF 035 and in NON 046 ( Figure 1B ). Effective arterial elastance (cEa), calculated as central aortic end-systolic blood pressure divided by stroke volume, was higher in affected family members ( Figure 1C ). Left ventricular end-systolic elastance, calculated by a modified single-beat method but factoring in central systolic blood pressure and central diastolic blood pressure, was also higher in affected family members. The ratio between Ea and Ees-sb, which reflects the degree of ventriculoarterial coupling, was normal in both groups. Measurements during handgrip testing showed similar results. Cardiac visualization results were consistent with the clinical data. For instance, LV function of AFF 035 as assessed by multislice imaging with 4D echocardiography ( Figure S1 in the online-only Data Supplement), including quantification of the LV global and regional function by longitudinal strain bull's eye with averaged values for the 17 LV segments and corresponding curves. Affected persons showed no profound changes in left ventricular mass, cardiac output, or distensibility of the ascending aorta measured by CMR. We performed cardiac MRI and covered completely the left ventricle to quantify volume and function. These images from AFF 035 Listed are the status as affected (AFF) and nonaffected (NON); age in years; sex classified as male and female; height in cm; weight in kg; body mass index (BMI) in kg/mattest to the normal cardiac function in these subjects determined by CMR ( Figure 2) .
In cardiac myocytes, PDE3A1 interacts with a multiprotein complex, which contains A-kinase anchoring protein (AKAP18) and sarcoplasmic reticulum Ca 2+ ATPase 2 (SERCA2A), and controls Ca 2+ reuptake into the sarcoplasmatic reticulum. This localization at the sarcoplasmatic reticulum involves Ser 292 /Ser 293 phosphorylation of PDE3A1. 28, 29 We , and the cEa/Ees-sb ratio (cEa/Ees-sb, right) in aff and nonaff family members measured by echocardiography (Echo). All affected are symbolized using gray, and the nonaffected are symbolized using black color. Nonaff 046 was hypertensive, obese, and had atherosclerosis (large diamond-shaped symbol). aimed to elucidate whether the 6 HTNB-causing PDE3A mutations that affect its phosphorylation at Ser 428 and Ser 438 also had an effect on compartmentalization. In PMA/forskolin-stimulated cells, we observed a slight increase of the mutational PDE3A1 isoforms phosphorylated at Ser 428 in the microsomal fraction, supporting the idea that mutation-dependent increased Ser 428 phosphorylation leads to an enhanced association of the mutational enzymes to the membrane ( Figure S2 ).
We found no differences in platelet aggregation by activation using TRAP or collagen (Table S1 ). Although the data suggest a minor but consistent shift in the platelets responsiveness to milrinone, as an inhibitor of platelet aggregation in affected individuals, the high interindividual variability does not allow demonstrating a statistical significance of this effect. We compared the PDE3A isoforms of human cardiac tissue, HeLa cells, and transiently transfected HeLa cells expressing full-length wild-type PDE3A versus platelet PDE3A by Western blotting. We illustrate the identified mutation sites, the known PDE3A isoforms, their relationship to the catalytic domain, and the protein domains recognized by the antibodies ( Figure 3A) . As expected, the 3 known isoforms, PDE3A1 (microsomal), PDE3A2, and PDE3A3 (both microsomal and cytosolic), were detected in the cardiac tissue and in transfected HeLa cells. Platelets expressed predominantly the PDE3A2 isoform ( Figure 3B) . 30 Intense signals of the antibody to PDE3A phosphoS 438 were observed, suggesting a highly phosphorylated PDE3A2 isoform on platelet activation with TRAP-6 or collagen.
To test for possible pharmacological intervention aiming at increasing cAMP levels, HeLa cells were transfected with full-length wild-type or 1 of the 6 full-length PDE3A mutational expression constructs and with a cAMP responsive element regulating luciferase transcriptional activity. Increasing forskolin concentrations enhanced the endogenous cAMP levels. Previously, we have shown that the PDE3 mutations in the sole presence of forskolin or l-arginine showed a significant reduction of the cAMP responsive element-mediated luciferase activity as a result of the higher cAMP hydrolysis when compared with wild-type PDE3A (http://www.nature.com/ ng/journal/v47/n6/fig_tab/ng.3302_SF6.html).
14 The mutated PDE3A proteins hydrolyzed more cAMP in the presence of cilostazol ( Figure 4A ) compared with controls (P<0.002). Milrinone decreased (P<0.002) the enhanced cAMP hydrolysis more effectively than cilostazol with increasing cAMP levels ( Figure 4B ). The effect on the mutants was less than on wild-type PDE3A cAMP hydrolysis. Moreover, PDE3A was competitively inhibited by cGMP. 31 cGMP stimulation using cilostazol showed that cGMP competitively inhibited cAMP hydrolysis with a significant (P<0.002) difference between mutants and wild-type PDE3A ( Figure 4C ). The data indicate that the more cGMP is present, the less was the cAMP hydrolysis, and the greater was the measured luciferase activity. Cilostazol abrogated the inhibitory effect of the increasing l-arginine concentrations on the mutants more (P<0.002) than on the wild-type PDE3A ( Figure 4C ). The cGMP inhibition and milrinone inhibition were synergistic and equalized the mutant and the wild-type PDE3A hydrolytic activities ( Figure 4D ). The soluble guanylate cyclase stimulator, BAY 41 to 8543, reduced the enhanced cAMP hydrolysis of the PDE3A mutations to the levels of the wild-type PDE3A ( Figure 4E ).
Discussion
We determined earlier that HTNB featured increased peripheral vascular resistance without salt sensitivity. 5 In that study, we also found that fibroblasts from the patients proliferated at a slightly increased rate, compared controls. Analogous observations have been made earlier in VSMC in spontaneously hypertensive rats. 32 Results from our recent study confirmed our earlier observations. 8, 14 We also observed altered phosphorylation of vasodilator-stimulated phosphoprotein that could influence VSMC proliferation and function. 33 The findings bring to mind the arguments raised by Folkow, 34 who taught that vascular hypertrophy, remodeling, and reactivity could be a driver of peripheral vascular resistance in hypertension. 35 Also contributing to an increase in peripheral vascular resistance is an increase in myosin light-chain phosphorylation via myosin light-chain kinase. Myosin light-chain kinase is inhibited through protein kinase A-mediated effects brought about by the balance between cGMP and cAMP hydrolysis. In the presence of our mutations, this inhibition is decreased ( Figure S3 ). 36, 37 As a result, cAMP is degraded at a slightly increased rate. We suggest, as a consequence, the braking effect of protein kinase A on myosin light-chain kinase is lifted resulting in increased VSMC contraction.
Recently, Kurtz et al 38 drew attention to the Mendelian disorders that are associated with abnormalities in distal sodium transport. They propose that the disorders should exhibit an impaired ability to vasodilate and lower systemic vascular resistance in response to increases in salt intake. We subjected our subjects to a standardized volume-expansion, volumecontraction protocol >20 years ago and found that their blood pressure was salt and volume independent. 5 Kurtz et al 38 pointed out that a subnormal ability to conduct vasodilation in response to salt loading could be caused by mutation-related disturbances originating in the vasculature itself or in sites outside the vasculature, such as brain or adrenal glands, that have the capacity to affect vascular function. We would support such an interpretation. We aimed to study ventriculoarterial coupling in patients with HTNB during rest and isometric handgrip challenge. Under normal conditions, the heart and the vasculature are fine tuned in structure and function to maintain the oxygen supply for peripheral organs and demand at a minimum of energy consumption. The relationship between the heart and the vasculature is well maintained in animals at different levels of volume load and during exercise. 39, 40 Several groups have proposed a new approach to evaluate the interaction between the ventricle and the vasculature based on the relation between LV end-systolic elastance (Ees) and Ea in health and disease. According to Chen et al, 41 left ventricular end-systolic elastance can be calculated by a modified single-beat method using systolic (P(s)) and diastolic (P(d)) arm-cuff pressures, echo-Doppler stroke volume, and echo-derived ejection. Experimental and clinical studies have tended to focus on optimized external work or efficiency. An Ea/Ees coupling ratio of 0.6 to 1.2 is close to optimal efficiency. This range is normally maintained under various physiological stresses. However, the coupling ratio can become high in systolic heart failure, where depressed systolic function (low Ees) is coupled to high arterial impedance (high Ea). In the observations reported here, we could detect no differences between 14 Cilostazol showed no effect abrogating the PDE3A mutations gain-offunction effects. B, Milrinone decreased the enhanced cAMP hydrolysis more effectively than cilostazol with increasing cAMP levels. C, cGMP stimulation with increasing l-arginine concentrations and cilostazol had light effects blocking the enhanced cAMP hydrolysis. D, cGMP in combination with milrinone determined that cGMP competitively inhibited cAMP hydrolysis. E, The soluble guanylate cyclase stimulator BAY 41-8543 reduced the enhanced cAMP hydrolysis of the PDE3A mutations compared with the wild-type PDE3A. **P<0.002, mean±SD; n=3; Wilcoxon and Mann-Whitney test).
by guest on July 31, 2017 http://hyper.ahajournals.org/ Downloaded from affected and nonaffected persons. Cardiac function and morphology were remarkably normal in affected persons, similar to our earlier observations. 5 The findings raise the hypothesis that perhaps the PDE3A overactivity somehow protects the heart from injury.
Earlier observations support the idea that phosphoinositide 3-kinase (PI3Kγ) coordinates the coincident signaling of the major cardiac PDE3 and PDE4 isoforms, thus orchestrating a feedback loop that prevents calcium-dependent ventricular arrhythmia. 42 Other investigators examined the role of PDE3A in regulating myocardial function and survival in vivo using transgenic mice with myocardial PDE3A1 overexpression. These mice were protected against ischemia-reperfusion injury presumably because of reduced β-adrenergic receptor-mediated signaling. 43 Still other investigators used the same transgenic overexpression model to determine PDE3A-related effects on angiotensin-II-induced cardiac hypertrophy. 44 The findings suggested that PDE3A protects the heart from angiotensin-IIinduced cardiac remodeling through its modulation of the functional connection between angiotensin-II and transforming growth factor-β. Although PDE3A2 is the prominent isoform in VSMC, PDE3A1 associates with SERCA2, phospholamban, and AKAP18 in a multiprotein signalosome in human cardiac sarcoplasmatic reticulum, where it regulates a discrete cAMP pool that controls contractility by modulating Ca 2+ reuptake into the sarcoplasmatic reticulum during diastole. 29 Our preliminary experiments using a HeLa cell transfection model suggest that increased phosphorylation at Ser 428 promote association of the mutational PDE3A1 isoforms with the membrane fraction. PDE3 inhibitors are used for acute treatment of heart failure, but are associated with increased incidence of arrhythmias and sudden death with long-term use. 45 However, these patients had severe heart failure and only a limited life expectancy. PDE3 inhibitors have found a therapeutic niche in the treatment of pulmonary hypertension. 46 Nonetheless, the negative milrinone results probably preclude our trying this PDE3 inhibitor as a blood pressure-lowering agent in HTNB patients.
The second messenger cAMP is a major inhibitor of platelet activation pathways. Although PDE2A (cGMP-stimulated cAMP-PDE) and PDE5A (cGMP-specific PDE) are expressed in platelets, the cGMP-inhibited PDE3A is the most abundant PDE in platelets regulating basal cAMP levels, and an effective target for antiplatelet agents. 20 We expected that PDE3A hyperactivity mediated by mutations in HTNB would result in increased platelet function and elevated aggregation in our affected subjects, which could contribute to stroke. However, we observed no differences in platelet aggregation between mutation carriers and nonaffected family members using TRAP and collagen. In contrast to PDE3A1 and PDE3A2 carrying the T445N mutation that need >300-fold higher concentrations of milrinone for inhibition than the wild-type enzyme, 14 the platelet PDE3A isoform of affected subjects was slightly more responsive to the inhibitor than to the platelet enzyme of the nonaffected relatives. The enhanced activity of the mutant PDE3A1 and PDE3A2 isoforms is caused by an increased Ser 428 and Ser 438 phosphorylation. 14 We found that platelets derived from a control person showed brisk phosphorylation of PDE3A2 at Ser 438 on stimulation with TRAP-6 or collagen. Hunter et al 47 observed that platelet activation stimulates protein kinase C-dependent phosphorylation of PDE3A on various serine residues, among others Ser 428 and Ser
438
, leading to a subsequent increase in cAMP hydrolysis. 47 We postulate that platelet activation induces nearly saturated phosphorylation of residue Ser 438 that would impede and compensate the effects of the PDE3A mutations on the phosphorylation status, as well as the hydrolytic activity of the enzyme in our HTNB patients. Furthermore, the T445N mutation could support the interaction of the enzyme with milrinone in platelets.
We investigated the pharmacological effects of milrinone, cilostazol, and a soluble guanylate cyclase stimulator in cells expressing each of the 6 PDE3A mutational variants.
14 These studies indicated that mutated PDE3A was associated with increased cAMP-hydrolytic activity, even when exposed to the stimulator of adenylate cyclase, forskolin. We found that milrinone and cilostazol diminished the increased PDE3A activity. Adding arginine helped, presumably by generating cGMP, which inhibits binding and hydrolysis of cAMP. The cGMP also activates cGMP-dependent protein kinase G1. Eliminating the binding of PKG1 to myosin light-chain phosphatase leads to VSMC abnormalities of contraction, relaxation, and systemic blood pressure in mice, independently of the renal function, 48 a situation similar to that in our patients. Increasing cGMP by stimulating soluble guanylate cyclase has developed into a sound, promising, therapeutic concept 49 and has shown utility in pulmonary hypertension. 50 Augmenting natriuretic peptide-mediated cGMP production, physical exercise, or neprilysin inhibition could all ameliorate cAMP deficiency in affected persons.
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Perspectives HTNB is a novel Mendelian model of increased peripheral vascular resistance. The current clinical data of patients carrying the PDE3A T445N mutation suggest that function of platelets is not affected and that the effects of the hyperactive enzyme may actually be cardioprotective. The mechanism of hypertension is increased peripheral resistance from vasoconstriction, vascular remodeling, or both. Our preliminary data suggest that soluble guanylate-cyclase stimulation could be of clinical benefit in this syndrome and perhaps in difficult-tocontrol hypertension in general.
Supplemental methods
Echocardiography
Assessment of LVEF took place at rest and during the third minute of isometric handgrip testing using standardized 4-and 2-chamber views. For assessment of systemic flow at rest and during handgrip testing, we obtained a velocity time integral by pulsed Doppler in the left ventricular outflow tract (LVOT). The systolic diameter of the LVOT was obtained from parasternal long axis view.
Cardiac output at rest and during handgrip test was calculated using the postprocessing platform EchoPAC (GE Healthcare) for one representative R-R interval with two methods. First, we used two-dimensional volume measurements with the biplane method of disks summation (modified Simpson's rule) based on the manual tracing of endocardial border. Papillary muscles were excluded from the cavity. Second, we relied on the product of the velocity-time integral (VTI) and the crosssectional area (CSA) of the LVOT.
Cardiac magnetic resonance (CMR)
Furthermore, we acquired a double-oblique parasagittal image of the aorta to estimate the path length of the pulse wave along the aorta. All CMR imaging was done under resting conditions, but pulse wave velocity was estimated also following standardized stress. Subjects performed isometric handgrip exercise over a 3-minute stress period adjusting the pressure force at 30% of their individual maximum. 1 Imaging and semiautomatic blood pressure measurement on the contralateral upper arm was started synchronously after 2 min handgrip exercise completing all acquisitions within 3 min.
Parameters of cardiac volumes and stroke volume were received from manual endo-contouring of end-systolic and end-diastolic short-axis images using cvi 42 (circle cvi, Calgary, Canada). For estimation of distensibility at the different aortic levels maximum and minimum areas of the aorta were determined from manual tracing of the vessel lumen. To estimate pulse wave velocity, the temporal delay of the pulse wave between ascending aorta and abdominal aorta was calculated from flow velocity curves and finally divided by the distance between these points. For this purpose, we acquired cine and phase-contrast images perpendicular to the flow direction at three aortic levels: ascending aorta and descending aorta at the level of the pulmonary artery bifurcation and abdominal aorta 5 cm below the diaphragm.
Immunoblotting of transiently transfected HeLa, platelet, and human heart tissue lysate PBS washed platelet aggregates were resuspended in RIPA buffer supplemented with protease and phosphatase inhibitors, homogenized ultrasonically (Bandelin SONOPULS) and subsequently centrifuged (15 min, 4°C, 21,250 x g). Human cardiac tissue was homogenized in RIPA buffer supplemented with protease and phosphatase inhibitors using a speed mill (SpeedMill P12; Analytik Jena AG). The cell homogenate was incubated for 30 min on ice followed by centrifugation (15 min, 4°C, 21,250 x g). The cleared lysates (transfected HeLa cells, platelet and human cardiac tissue) were quantified with Coomassie PlusTM Protein Assay Reagent (Thermo Scientific) and 20 µg of total protein of HeLa lysate and 50µg of total protein of platelet and human cardiac lysate were used for immunoblotting according to standard protocols. Detection of PDE3A isoforms was performed with antibodies to PDE3A (A302-740A; Bethyl Laboratories Inc. and SC-11830; Santa Cruz Biotechnology) and antibodies to PDE3A phospho-serine 428 and 438 (S446B
Cell-based studies
The data describe the relative increase of luciferase activity normalized to the DMSO control of empty-vector transfected cells. 5x104 HeLa cells were seeded 12-24 h prior to transfection. 75 fmol each of the CRE-luciferase construct (pGL4.29, Promega) and the full-length wildtype PDE3A or full-length mutation constructs were transfected with Fugene Extreme Gene HP (Roche), according to the manufacturer's recommendations. 12.5 ng of pRL-TK (Promega) were added to control transfection efficiency. After 48 h of transfection cell lysates were analyzed using the Dual-Glo Assay (Promega) in a Berthold luminometer. 4 h prior to cell lysis, forskolin (0.3; 1; 10 M) was added. L-Arginine (1; 30; 100 M) was added for 10-15 min before cell lysis. The media of transfected HeLa cells was supplemented with BAY 41-8543 (1; 30; 100 M; kindly provided by Dr. Damian Brockschnieder, Bayer AG), 30 min before harvesting. The compound (0.5 mg/ml) was solved in dimethyl formamide (DMF):PBS (pH 7.2), 1:1. DMSO or DMF served as controls. The results are means of three independent transfections (mean±SD; n = 3; Wilcoxon-Mann-Whitney test). (A) The fractionation of transfected and non-stimulated HeLa cells showed no differences in compartmentalization between endogenous or wildtype PDE3A and mutational PDE3A. As previously described, the A1 isoform was predominantly detected in the membrane fraction, the A2 isoform mainly in the cytosol. Hsp90 was positive marker for cytosolic fraction, whereas PanCad (Pan Cadherin) was in the membrane fraction. (B) In PMA-and forskolin-stimulated transfected HeLa cells, a slight increase of mutational PDE3A1 was detected in microsomal fractions using the polyclonal anti-PDE3A antibody A302-740A (Bethyl Laboratories Inc.). The mutational PDE3A1 shows a modest increased Ser428 phosphorylation that could lead to an enhanced association of the enzyme to the membrane. The schematic shows overactive PDE3A hydrolyzing cAMP, impacting on protein kinase A (PKA), myosin light-chain kinase (MLCK) and the phosphorylation of myosin light chain (MLC). We speculate that altered vasodilator-stimulated phosphoprotein phosphorylation (pVASP) could influence VSMC proliferation.
